League table of association between pharmacologic treatments and changes in depressive symptom severity
| Methylphenidate | −0.86 (−1.77 to 0.04) | −0.91 (−1.55 to −0.28)* | ||||
| −0.09 (−1.84 to 1.66) | Desipramine | −0.82 (−2.44 to 0.81) | ||||
| −0.41 (−1.64 to 0.82) | −0.32 (−2.29 to 1.66) | Escitalopram | −0.50 (−1.53 to 0.54) | |||
| −0.65 (−1.26 to −0.03)* | −0.55 (−2.23 to 1.12) | −0.24 (−1.35 to 0.88) | Sertraline | −0.28 (−0.54 to −0.02)* | ||
| −0.74 (−1.60 to 0.11) | −0.65 (−2.42 to 1.12) | −0.33 (−1.59 to 0.92) | −0.10 (−0.79 to 0.59) | Atomoxetine | −0.16 (−0.71 to 0.39) | |
| −0.95 (−1.77 to −0.12)* | −0.86 (−2.61 to 0.90) | −0.54 (−1.77 to 0.69) | −0.30 (−0.95 to 0.35) | −0.20 (−1.06 to 0.66) | Melatonin | 0.04 (−0.45 to 0.53) |
| −0.91 (−1.49 to −0.33)* | −0.81 (−2.47 to 0.84) | −0.50 (−1.58 to 0.59) | −0.26 (−0.54 to 0.01) | −0.16 (−0.79 to 0.47) | 0.04 (−0.54 to 0.63) | Placebo |
CI = confidence interval; SMD = standardized mean difference.
Results of pair-wise (right side of row) and network (left side of row) meta-analysis are presented as estimate effect sizes for postintervention depressive severity. Interventions are reported in order of mean ranking of treatment effect, and outcomes are expressed as SMD (95% CI). For pair-wise meta-analyses, an SMD of less than 0 indicates that the treatment specified in the row led to better improvement in depressive severity than the treatment specified in the column. For network meta-analysis, an SMD of less than 0 indicates that the treatment specified in the column led to better improvement in depressive severity than the treatment specified in the row.
↵* Statistically significant (p < 0.05).